<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Systemic Lupus Erythematosus - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Systemic Lupus Erythematosus</span>
        </nav>

        <header class="page-header">
            <h1>Systemic Lupus Erythematosus</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0007915" target="_blank">
                        MONDO:0007915
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">15</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">13</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">23</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">musculoskeletal system disorder</span>
                    
                    <span class="tag tag-classification">connective tissue disease</span>
                    
                    <span class="tag tag-classification">autoimmune disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Discoid Lupus Erythematosus
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Primarily affects the skin.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30988213" target="_blank">PMID:30988213</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and..."</div>
                
                
                <div class="evidence-explanation">Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7763220" target="_blank">PMID:7763220</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement."</div>
                
                
                <div class="evidence-explanation">This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28941498" target="_blank">PMID:28941498</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types."</div>
                
                
                <div class="evidence-explanation">This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Neonatal Lupus
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Affects infants, caused by transplacental transfer of maternal autoantibodies.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9287379" target="_blank">PMID:9287379</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies."</div>
                
                
                <div class="evidence-explanation">This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24763535" target="_blank">PMID:24763535</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB)."</div>
                
                
                <div class="evidence-explanation">The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15744116" target="_blank">PMID:15744116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta."</div>
                
                
                <div class="evidence-explanation">This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                </div>
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Drug-Induced Lupus
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by certain medications and usually reversible.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1356074" target="_blank">PMID:1356074</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE."</div>
                
                
                <div class="evidence-explanation">This indicates that there is a distinct subtype of SLE induced by medications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23164669" target="_blank">PMID:23164669</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal."</div>
                
                
                <div class="evidence-explanation">This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1751313" target="_blank">PMID:1751313</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus..."</div>
                
                
                <div class="evidence-explanation">This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">15</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Formation of Immune Complexes</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        plasma cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000786" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Immunoglobulin production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0002377" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Complement activation, classical pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006958" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        B cell mediated immunity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0019724" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27709413" target="_blank">PMID:27709413</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Here, we review what is known on the altered metabolic patterns of CD4(+) T cells, B cells, and myeloid cells in lupus patients and lupus-prone mice and how they contribute to lupus pathogenesis."</div>
                
                
                <div class="evidence-explanation">The reference discusses the altered metabolic patterns of B cells, CD4(+) T cells, and myeloid cells (which include macrophages) and their contribution to lupus, which indirectly supports the involvement of these cell types in lupus mechanisms, but it does not specifically address immune complex formation directly.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29925508" target="_blank">PMID:29925508</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus."</div>
                
                
                <div class="evidence-explanation">This reference demonstrates the role of specific plasma cells in the development of lupus nephritis, implying their role in immune complex-related pathology, but does not detail the direct involvement of B cells or macrophages in immune complex formation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34402453" target="_blank">PMID:34402453</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"B-lymphocytes are crucial in the pathogenesis of systemic lupus erythematosus (SLE), including autoantibody production, antigen presentation, co-stimulation, and cytokine secretion."</div>
                
                
                <div class="evidence-explanation">The reference highlights the crucial role of B cells in the pathogenesis of SLE through mechanisms such as autoantibody production, which is critical for immune complex formation. However, it does not explicitly discuss the role of plasma cells or macrophages in the context given.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Glomerular Immune Complex Deposition</div>
                
                <div class="item-desc">Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies lodge in kidney glomeruli, activating complement and recruiting inflammatory cells.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        complement activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Kidney
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002113" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33841392" target="_blank">PMID:33841392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges. Deposition of immune complexes in kidneys glomeruli are associated with lupus nephritis, determining SLE diagnosis."</div>
                
                
                <div class="evidence-explanation">The literature supports the deposition of immune complexes in kidney glomeruli but does not cover skeletal joints, skin, heart, or lung in this context.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30009962" target="_blank">PMID:30009962</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins."</div>
                
                
                <div class="evidence-explanation">This confirms immune complex deposition in kidneys.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cutaneous Immune Complex Deposition</div>
                
                <div class="item-desc">Immune complexes deposit at the dermal-epidermal junction and in vessel walls of the skin, leading to cutaneous manifestations of lupus.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Skin
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002097" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35872103" target="_blank">PMID:35872103</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS)."</div>
                
                
                <div class="evidence-explanation">This paper directly establishes that autoantibodies form immune complexes which cause inflammatory damage to multiple organs in SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16572034" target="_blank">PMID:16572034</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune..."</div>
                
                
                <div class="evidence-explanation">The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Synovial Immune Complex Deposition</div>
                
                <div class="item-desc">Immune complexes accumulate in synovial fluid and tissue of joints, activating complement and triggering inflammatory arthritis.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        complement activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Skeletal Joint
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000982" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16572034" target="_blank">PMID:16572034</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune..."</div>
                
                
                <div class="evidence-explanation">The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2860699" target="_blank">PMID:2860699</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis,..."</div>
                
                
                <div class="evidence-explanation">This confirms immune complex deposition in the heart.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28900675" target="_blank">PMID:28900675</a>
                    </span>
                    
                    <span class="evidence-support support-WRONG_STATEMENT">WRONG_STATEMENT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recent studies demonstrated an increased incidence of osteoporosis and peripheral and vertebral fractures in patients with SLE"</div>
                
                
                <div class="evidence-explanation">This reference does not mention the deposition of immune complexes in skeletal joints.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Inflammation And Tissue Damage</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22192660" target="_blank">PMID:22192660</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage."</div>
                
                
                <div class="evidence-explanation">The article describes inflammation and immune complex deposition as mechanisms leading to tissue damage in SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36555640" target="_blank">PMID:36555640</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues."</div>
                
                
                <div class="evidence-explanation">The literature explains that inflammation and tissue damage are core mechanisms in the pathology of SLE due to immune system disturbances.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28623084" target="_blank">PMID:28623084</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. A complex interaction of genetics, environment, and hormones leads to immune dysregulation and breakdown of tolerance to self-antigens, resulting in autoantibody production, inflammation, and..."</div>
                
                
                <div class="evidence-explanation">This article outlines inflammation as part of the immune dysregulation in SLE, leading to tissue damage in multiple organs.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chronic Inflammation</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16572034" target="_blank">PMID:16572034</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues..."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that inflammation is a key aspect of systemic lupus erythematosus pathogenesis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26330673" target="_blank">PMID:26330673</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus, the prototype systemic autoimmune disease, is characterized by extensive self-reactivity, inflammation, and organ system damage."</div>
                
                
                <div class="evidence-explanation">The abstract clearly mentions inflammation as a characteristic feature of SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32237942" target="_blank">PMID:32237942</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ."</div>
                
                
                <div class="evidence-explanation">The literature describes SLE as a chronic autoimmune disease affecting various organs, implying sustained inflammation over time.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Flare-Ups</div>
                
                <div class="item-desc">The symptoms of lupus can worsen suddenly in episodes known as flares, which can be triggered by factors like stress, sunlight, and infections.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26951252" target="_blank">PMID:26951252</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms."</div>
                
                
                <div class="evidence-explanation">This reference mentions the potential triggers for lupus flares, which include UV light (sunlight) and infections.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26494589" target="_blank">PMID:26494589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Some triggers for these exacerbations have been identified, including infections, vaccines, pregnancy, environmental factors such as weather, stress and drugs."</div>
                
                
                <div class="evidence-explanation">This reference specifically states that stress and infections can trigger lupus flares.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22385883" target="_blank">PMID:22385883</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus."</div>
                
                
                <div class="evidence-explanation">This reference confirms that sunlight exposure can trigger lupus flares.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Type I Interferon Pathway Activation</div>
                
                <div class="item-desc">Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        plasmacytoid dendritic cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000784" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        type I interferon signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0060337" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24834763" target="_blank">PMID:24834763</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE."</div>
                
                
                <div class="evidence-explanation">This review describes the type I interferon gene signature in SLE, supporting chronic activation of the type I interferon pathway.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TLR7/TLR9-Mediated Nucleic Acid Sensing</div>
                
                <div class="item-desc">B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        plasmacytoid dendritic cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000784" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        toll-like receptor signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0002224" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        toll-like receptor 7 signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034154" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        toll-like receptor 9 signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034162" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">NETosis and Neutrophil Extracellular Trap Formation</div>
                
                <div class="item-desc">Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        neutrophil degranulation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        neutrophil extracellular trap formation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0036230" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Age-Associated B Cell Expansion</div>
                
                <div class="item-desc">Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        B cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042113" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        B cell differentiation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030183" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">T Follicular Helper Cell Dysregulation</div>
                
                <div class="item-desc">T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        T follicular helper cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002038" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        T cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042110" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        germinal center formation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0002467" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired Apoptotic Cell Clearance</div>
                
                <div class="item-desc">Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        apoptotic cell clearance
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043277" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        efferocytosis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043277" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Complement Pathway Dysregulation</div>
                
                <div class="item-desc">Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        complement activation, classical pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006958" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Kidney
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002113" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Glomerulus
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000074" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epigenetic Dysregulation and T Cell Metabolic Reprogramming</div>
                
                <div class="item-desc">Aberrant DNA methylation, histone modifications, and metabolic reprogramming in T cells contribute to lupus pathogenesis. Hypomethylation of immune gene loci activates autoreactive T cells, while metabolic shifts including altered mTOR signaling and glutaminolysis support inflammatory T cell programs.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD4-positive helper T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000492" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Epigenetic Regulation of Gene Expression
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0040029" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        T Cell Differentiation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030217" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Autoantibody Production&#39; (from &#39;Epigenetic Dysregulation and T Cell Metabolic Reprogramming&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Autoantibody_Production[&#34;Autoantibody Production&#34;]
    Lupus_Nephritis[&#34;Lupus Nephritis&#34;]
    Glomerular_Immune_Complex_Deposition[&#34;Glomerular Immune Complex Deposition&#34;]
    Epigenetic_Dysregulation_and_T_Cell_Metabolic_Reprogramming[&#34;Epigenetic Dysregulation and T Cell Metabolic Reprogramming&#34;]

    Glomerular_Immune_Complex_Deposition --&gt; Lupus_Nephritis
    Epigenetic_Dysregulation_and_T_Cell_Metabolic_Reprogramming -.-&gt; Autoantibody_Production

    style Autoantibody_Production fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Lupus_Nephritis fill:#fef3c7
    style Glomerular_Immune_Complex_Deposition fill:#dbeafe
    style Epigenetic_Dysregulation_and_T_Cell_Metabolic_Reprogramming fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">13</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Blood<span class="pill-count">(3)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Genitourinary<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Immune<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Integument<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Nervous System<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-8">Respiratory<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-9">Other<span class="pill-count">(2)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Blood
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Leukopenia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001882" target="_blank">
                                Decreased total leukocyte count
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001882)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Low white blood cell count</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26170228" target="_blank">PMID:26170228</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The prevalence of leukopenia is reported in 22-41.8% of cases."</div>
                
                
                <div class="evidence-explanation">The study reports that leukopenia is prevalent in 22-41.8% of SLE cases, indicating that leukopenia is a frequent hematologic abnormality in SLE patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27590999" target="_blank">PMID:27590999</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TCP was the most prevalent hematological abnormality evident in 15%, more than leucopenia (14%) and anemia (2%)."</div>
                
                
                <div class="evidence-explanation">Although thrombocytopenia was the most prevalent, leukopenia was still present in 14% of the cases, supporting the statement that leukopenia is a frequent hematologic abnormality in SLE patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8130682" target="_blank">PMID:8130682</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The increased risk of infection in patients with SLE is due in part to changes in the white blood cells though treatments do not yet aim to modify these."</div>
                
                
                <div class="evidence-explanation">The study mentions changes in white blood cells, including leukopenia, as a common hematologic manifestation in SLE patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Thrombocytopenia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001873" target="_blank">
                                Thrombocytopenia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001873)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Low platelet count</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32896257" target="_blank">PMID:32896257</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thrombocytopenia was classified as mild (100-149x109/L), moderate (31-99x109/L) or severe (&lt;/=30x109/L platelets)."</div>
                
                
                <div class="evidence-explanation">The study shows that thrombocytopenia is a common occurrence in SLE patients, with a significant portion experiencing various degrees of thrombocytopenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12481500" target="_blank">PMID:12481500</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thrombocytopenia is common, autoimmune and associated with a decreased survival."</div>
                
                
                <div class="evidence-explanation">This reference confirms that thrombocytopenia is a common hematologic abnormality in SLE patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15580984" target="_blank">PMID:15580984</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thrombocytopenia (&lt; 100,000/microL in the absence of offending drugs) is now considered as a single hematologic disorder."</div>
                
                
                <div class="evidence-explanation">This review highlights thrombocytopenia as a significant hematologic criterion for diagnosing SLE.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hemolytic Anemia
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001878" target="_blank">
                                Hemolytic anemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001878)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Destruction of red blood cells</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12481500" target="_blank">PMID:12481500</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Anaemia is the most common hematological abnormality in SLE, it is multifactorial. The most common form of anaemia is that of chronic disease, and it is relate with inflammatory cytokines. Other tips of anaemia are: iron deficiency anaemia, autoimmune haemolytic anaemia, pure red cell aplasia."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that autoimmune hemolytic anemia is one of the types of anemia in SLE but does not provide information about its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36469203" target="_blank">PMID:36469203</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that would potentiate many pathological complications, including hemolytic anemia."</div>
                
                
                <div class="evidence-explanation">This reference confirms that hemolytic anemia is one of the complications of SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15580984" target="_blank">PMID:15580984</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis)... is now considered as a single hematologic disorder."</div>
                
                
                <div class="evidence-explanation">The ACR criteria for diagnosing SLE includes hemolytic anemia as one of the hematologic disorders.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pericarditis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001701" target="_blank">
                                Pericarditis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001701)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Inflammation of the pericardium (lining around the heart)</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16218467" target="_blank">PMID:16218467</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pericarditis is the most common cardiac abnormality in systemic lupus erythematosus (SLE) patients..."</div>
                
                
                <div class="evidence-explanation">The literature states that pericarditis is the most common cardiac abnormality in SLE patients, not occasional.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31507126" target="_blank">PMID:31507126</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Several diseases are frequently associated with such manifestations. They include systemic lupus erythematosus..."</div>
                
                
                <div class="evidence-explanation">The literature indicates that systemic lupus erythematosus is frequently associated with pericarditis, not occasionally.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33216192" target="_blank">PMID:33216192</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pericarditis can be present in the context of systemic inflammatory rheumatic diseases..."</div>
                
                
                <div class="evidence-explanation">The literature suggests that pericarditis can commonly be present in systemic inflammatory rheumatic diseases, including SLE.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Genitourinary
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lupus Nephritis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0033726" target="_blank">
                                Lupus nephritis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0033726)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Inflammation of the kidneys, can lead to renal failure</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16530602" target="_blank">PMID:16530602</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lupus nephritis is one of the more serious manifestations of the systemic autoimmune disease, systemic lupus erythematosus, and is associated with considerable morbidity and even mortality."</div>
                
                
                <div class="evidence-explanation">The reference confirms that lupus nephritis is a serious and frequent manifestation of systemic lupus erythematosus (SLE).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32295853" target="_blank">PMID:32295853</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The frequency of endstage renal disease (ESRD) from systemic lupus erythematosus (SLE) in the United States has not improved over the last few decades in large population datasets."</div>
                
                
                <div class="evidence-explanation">The reference indicates the prevalence of renal complications, including end-stage renal disease, in SLE patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35775489" target="_blank">PMID:35775489</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lupus nephritis (LN) is common in people with systemic lupus erythematosus (SLE) and advances, almost invariably, to end-stage renal disease (ESRD)."</div>
                
                
                <div class="evidence-explanation">The reference supports that lupus nephritis is a common and serious renal manifestation in SLE, often leading to ESRD.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Immune
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Malar Rash
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0025300" target="_blank">
                                Malar rash
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0025300)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23846232" target="_blank">PMID:23846232</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The most common clinical manifestations were malar rash (61.3%)..."</div>
                
                
                <div class="evidence-explanation">The literature supports that malar rash is a common manifestation of systemic lupus erythematosus (SLE), but it does not specifically categorize it under &#39;Cutaneous&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16966017" target="_blank">PMID:16966017</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There are 3 forms of cutaneous lupus: chronic cutaneous (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus."</div>
                
                
                <div class="evidence-explanation">This reference discusses cutaneous forms of lupus but does not specifically mention malar rash as one of these types.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17711886" target="_blank">PMID:17711886</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The common symptoms of SLE in children and adolescents include... rash..."</div>
                
                
                <div class="evidence-explanation">This reference indicates that rash, which can include malar rash, is common in SLE, but it does not specifically categorize malar rash as &#39;Cutaneous&#39;.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Photosensitivity
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000992" target="_blank">
                                Cutaneous photosensitivity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000992)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15379880" target="_blank">PMID:15379880</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Photosensitivity is one the most common manifestations of lupus erythematosus."</div>
                
                
                <div class="evidence-explanation">The literature directly mentions that photosensitivity is a common manifestation in lupus erythematosus, supporting the statement that it is a frequent phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31909888" target="_blank">PMID:31909888</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fatigue, widespread pain, sleep dysfunction, and mood disorders are common symptoms in SLE."</div>
                
                
                <div class="evidence-explanation">While this reference mentions common symptoms of SLE, it does not specifically address photosensitivity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30988213" target="_blank">PMID:30988213</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The cutaneous manifestations of lupus erythematosus (LE) include LE-specific and LE-nonspecific skin lesions."</div>
                
                
                <div class="evidence-explanation">The reference discusses cutaneous manifestations of LE but does not specifically highlight photosensitivity.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arthritis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001369" target="_blank">
                                Arthritis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001369)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19591780" target="_blank">PMID:19591780</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Arthritis in systemic lupus erythematosus (SLE) is one of the most common disease manifestations. Nearly all joints can be affected by SLE, but hand and knee involvement are the most typical."</div>
                
                
                <div class="evidence-explanation">This reference explicitly states that arthritis is one of the most common disease manifestations in patients with SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27742023" target="_blank">PMID:27742023</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The precise nature of the disorder can be obscure and different disorders can present with similar symptoms, such as joint pain."</div>
                
                
                <div class="evidence-explanation">The statement mentions joint pain, which is associated with arthritis and suggests that musculoskeletal symptoms are common in SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19013374" target="_blank">PMID:19013374</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus is an autoimmune and inflammatory disease characterized by a variety of symptoms, including arthropathy. The clinical presentation of joint involvement varies, ranging from arthralgia without erosions or deformity to an erosive arthropathy and severe functional disability."</div>
                
                
                <div class="evidence-explanation">This reference elaborates on the different forms of joint involvement in SLE, including arthropathy, which reinforces the statement that arthritis is a common musculoskeletal phenotype in SLE.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33626435" target="_blank">PMID:33626435</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The prevalence of explicit episodes of seizures among SLE patients, varies from 2 to 8%."</div>
                
                
                <div class="evidence-explanation">The prevalence range of 2 to 8% suggests that seizures are not very common but occur at a noticeable rate, which could be interpreted as occasional.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12136236" target="_blank">PMID:12136236</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Seizures and psychosis are neuropsychiatric (NP) manifestations of a large number of systemic lupus erythematosus (SLE) patients."</div>
                
                
                <div class="evidence-explanation">This reference supports the idea that seizures are a recognized neuropsychiatric manifestation of SLE, implying they occur with some regularity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Psychosis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000709" target="_blank">
                                Psychosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000709)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30375754" target="_blank">PMID:30375754</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status."</div>
                
                
                <div class="evidence-explanation">The study indicates that psychosis is an infrequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), which suggests it is not common but does occur occasionally. This partially supports the statement that psychosis is an &#39;occasional&#39; manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37771217" target="_blank">PMID:37771217</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Psychosis is a rare NPSLE manifestation that can occur at any phase of the illness; 21% of SLE-related psychosis cases occur at the onset of SLE."</div>
                
                
                <div class="evidence-explanation">This case report describes psychosis as a rare manifestation of NPSLE, occurring in 21% of cases at the onset of SLE. While &#39;rare&#39; and &#39;occasional&#39; are not identical, they both imply infrequency, partially supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-8">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Respiratory
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pleuritis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002102" target="_blank">
                                Pleuritis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002102)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Inflammation of the pleura (lining around the lungs)</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8153398" target="_blank">PMID:8153398</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The pleuropulmonary manifestation of systemic lupus erythematous (SLE) are pleuritis, acute lupus pneumonitis, chronic interstitial lung disease with fibrosis, alveolar hemorrhage, respiratory muscle and diaphragmatic dysfunction, atelectasis, bronchiolitis obliterans, pulmonary vascular disease..."</div>
                
                
                <div class="evidence-explanation">The article explicitly lists pleuritis as one of the pleuropulmonary manifestations of SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25318967" target="_blank">PMID:25318967</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We investigated the clinical characteristics of pleural effusion in systemic lupus erythematosus (SLE). A prospective analysis of 17 SLE patients with pleural effusion (seven lupus pleuritis, eight transudative effusions and two parapneumonic effusions) was performed."</div>
                
                
                <div class="evidence-explanation">The prospective analysis found lupus pleuritis in SLE patients, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12055395" target="_blank">PMID:12055395</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fortunately, pleuritis in systemic lupus erythematosus is not usually as life threatening as may be the renal or central nervous system complications. Nevertheless, pleuritis does occur in systemic lupus erythematosus and may be a significant cause of morbidity."</div>
                
                
                <div class="evidence-explanation">The article confirms that pleuritis occurs in SLE patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-9">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Kidney Involvement
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36251502" target="_blank">PMID:36251502</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Among 365 patients with SLE, 36% had LN."</div>
                
                
                <div class="evidence-explanation">The study indicates that a significant portion of patients with Systemic Lupus Erythematosus (SLE) exhibit kidney involvement in the form of lupus nephritis (LN).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/330103" target="_blank">PMID:330103</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The pathologic abnormalities present in patients with SLE have been classified as follows: minimal lupus nephritis, mild (focal) proliferative lupus nephritis, severe (diffuse) proliferative lupus nephritis, and membranous lupus nephritis."</div>
                
                
                <div class="evidence-explanation">The classification of pathologic abnormalities in SLE patients includes various forms of lupus nephritis, which confirms kidney involvement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30454753" target="_blank">PMID:30454753</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with early onset SLE tend to have a greater genetic component to their disease cause, more multisystemic involvement, and a more severe disease course, which includes greater risks for developing nephritis and end-stage kidney disease."</div>
                
                
                <div class="evidence-explanation">This study highlights that childhood-onset SLE has a high risk of developing nephritis, underlining kidney involvement as a significant phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Kidney Involvement
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32725543" target="_blank">PMID:32725543</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kidney involvement occurs in over 50% of children and treatment decisions are guided by the histological classification."</div>
                
                
                <div class="evidence-explanation">The study discusses kidney involvement in pediatric SLE but does not categorize it as &#34;Hematologic phenotype&#34;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22312827" target="_blank">PMID:22312827</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a chronic syndrome with unknown etiology and polymorphic clinical picture... Severe SLE involves glomerulonephritis, complications in the central nervous system, cardiac and pulmonary complications and major changes in the blood."</div>
                
                
                <div class="evidence-explanation">The literature describes both hematologic changes and kidney involvement separately but does not categorically combine them into a single phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14717922" target="_blank">PMID:14717922</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis... The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions."</div>
                
                
                <div class="evidence-explanation">This paper details the classification of lupus nephritis but does not mention it as a hematologic phenotype.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">23</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DR2
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37801591" target="_blank">PMID:37801591</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis)"</div>
                
                
                <div class="evidence-explanation">The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DR3
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17910142" target="_blank">PMID:17910142</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01)."</div>
                
                
                <div class="evidence-explanation">The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6103441" target="_blank">PMID:6103441</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE."</div>
                
                
                <div class="evidence-explanation">This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PTPN22
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31232672" target="_blank">PMID:31232672</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p &lt; 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE."</div>
                
                
                <div class="evidence-explanation">The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    STAT4
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23912645" target="_blank">PMID:23912645</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE."</div>
                
                
                <div class="evidence-explanation">The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31082500" target="_blank">PMID:31082500</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4..."</div>
                
                
                <div class="evidence-explanation">This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34525002" target="_blank">PMID:34525002</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in..."</div>
                
                
                <div class="evidence-explanation">The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IRF5
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20962850" target="_blank">PMID:20962850</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE..."</div>
                
                
                <div class="evidence-explanation">The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26233721" target="_blank">PMID:26233721</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE..."</div>
                
                
                <div class="evidence-explanation">The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23251221" target="_blank">PMID:23251221</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis."</div>
                
                
                <div class="evidence-explanation">The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TLR7
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TLR9
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MYD88
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CYBB
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNFSF13B
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL21
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BACH2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNFAIP3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    STAT3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL10
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    EGR2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ETS1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IRF4
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IRF8
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IKZF1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SMAD3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    REL
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PRDM1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GWAS)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Type I Interferon Receptor Antagonist
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28130918" target="_blank">PMID:28130918</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE"</div>
                
                
                <div class="evidence-explanation">This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    B Cell Depletion Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    BAFF Pathway Inhibition
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22127708" target="_blank">PMID:22127708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE"</div>
                
                
                <div class="evidence-explanation">This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Immunosuppressive Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.</div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">UV Exposure</div>
                
                <div class="item-desc">Exacerbates disease activity.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24763542" target="_blank">PMID:24763542</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE."</div>
                
                
                <div class="evidence-explanation">The literature clearly states that UV radiation exposure may exacerbate pre-existing lupus, which supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22385883" target="_blank">PMID:22385883</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus."</div>
                
                
                <div class="evidence-explanation">The study investigates the seasonal variation in lupus flares and correlates increased flares with increased temperature and sunshine, supporting the statement that UV exposure exacerbates disease activity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Infection</div>
                
                <div class="item-desc">Can trigger or worsen disease symptoms.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36332998" target="_blank">PMID:36332998</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This review focuses on SLE risk potentially associated with environmental factors including infections."</div>
                
                
                <div class="evidence-explanation">The paper identifies infections as one of the environmental factors potentially associated with the risk of SLE, thereby supporting the statement that infections can trigger or worsen disease symptoms in SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25022358" target="_blank">PMID:25022358</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described."</div>
                
                
                <div class="evidence-explanation">This review mentions infections, specifically Epstein-Barr virus, as triggers for autoimmunity, which supports the notion that infections can influence SLE disease activity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38146370" target="_blank">PMID:38146370</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated."</div>
                
                
                <div class="evidence-explanation">This study supports the connection between infections (specifically EBV) and SLE, further establishing that infections can trigger or worsen SLE symptoms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Stress</div>
                
                <div class="item-desc">Psychological stress can trigger flares.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25216337" target="_blank">PMID:25216337</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals"</div>
                
                
                <div class="evidence-explanation">This reference discusses various environmental factors that can trigger SLE flares, which supports the notion that stress, as an environmental factor, can do so as well.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36537191" target="_blank">PMID:36537191</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined."</div>
                
                
                <div class="evidence-explanation">This reference directly supports the statement that psychological stress can trigger and worsen SLE flares.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36535611" target="_blank">PMID:36535611</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE."</div>
                
                
                <div class="evidence-explanation">This reference indicates a link between stress-related disorders and the development or worsening of SLE.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Nuclear Antibodies (ANA)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32884126" target="_blank">PMID:32884126</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction."</div>
                
                
                <div class="evidence-explanation">While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34996081" target="_blank">PMID:34996081</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent."</div>
                
                
                <div class="evidence-explanation">The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23456415" target="_blank">PMID:23456415</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Antinuclear antibody was present in 79.6%."</div>
                
                
                <div class="evidence-explanation">This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-dsDNA Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29224677" target="_blank">PMID:29224677</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens."</div>
                
                
                <div class="evidence-explanation">This supports the presence of anti-dsDNA antibodies in patients with SLE.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20414746" target="_blank">PMID:20414746</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN."</div>
                
                
                <div class="evidence-explanation">This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35049409" target="_blank">PMID:35049409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE)."</div>
                
                
                <div class="evidence-explanation">This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Smith Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29503043" target="_blank">PMID:29503043</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE."</div>
                
                
                <div class="evidence-explanation">The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Histone Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35383534" target="_blank">PMID:35383534</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE)."</div>
                
                
                <div class="evidence-explanation">The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35383534" target="_blank">PMID:35383534</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs."</div>
                
                
                <div class="evidence-explanation">While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Systemic Lupus Erythematosus
creation_date: &#39;2025-12-04T16:57:31Z&#39;
updated_date: &#39;2026-02-16T20:19:38Z&#39;
description: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific
category: Complex
parents:
- Autoimmune Disease
has_subtypes:
- name: Discoid Lupus Erythematosus
  description: Primarily affects the skin.
  evidence:
  - reference: PMID:30988213
    supports: SUPPORT
    snippet: The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE.
    explanation: Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.
  - reference: PMID:7763220
    supports: SUPPORT
    snippet: Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement.
    explanation: This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.
  - reference: PMID:28941498
    supports: SUPPORT
    snippet: Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types.
    explanation: This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.
- name: Neonatal Lupus
  description: Affects infants, caused by transplacental transfer of maternal autoantibodies.
  evidence:
  - reference: PMID:9287379
    supports: SUPPORT
    snippet: neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies.
    explanation: This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.
  - reference: PMID:24763535
    supports: SUPPORT
    snippet: Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB).
    explanation: The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.
  - reference: PMID:15744116
    supports: SUPPORT
    snippet: Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta.
    explanation: This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.
  - reference: PMID:3521977
    supports: SUPPORT
    snippet: &#39;Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus...&#39;
    explanation: This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors.
  - reference: PMID:22832822
    supports: PARTIAL
    snippet: Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy.
    explanation: This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn&#39;t explicitly say it&#39;s a systemic lupus erythematosus subtype.
- name: Drug-Induced Lupus
  description: Caused by certain medications and usually reversible.
  evidence:
  - reference: PMID:1356074
    supports: SUPPORT
    snippet: The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE.
    explanation: This indicates that there is a distinct subtype of SLE induced by medications.
  - reference: PMID:23164669
    supports: SUPPORT
    snippet: Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal.
    explanation: This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.
  - reference: PMID:1751313
    supports: SUPPORT
    snippet: All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself.
    explanation: This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.
  - reference: PMID:25037258
    supports: SUPPORT
    snippet: This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus...
    explanation: This article covers drug-induced lupus, affirming the existence of this subtype linked to medications.
pathophysiology:
- name: Formation of Immune Complexes
  biological_processes:
  - preferred_term: Immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
  - preferred_term: Complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  - preferred_term: B cell mediated immunity
    term:
      id: GO:0019724
      label: B cell mediated immunity
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  evidence:
  - reference: PMID:27709413
    supports: PARTIAL
    snippet: Here, we review what is known on the altered metabolic patterns of CD4(+) T cells, B cells, and myeloid cells in lupus patients and lupus-prone mice and how they contribute to lupus pathogenesis.
    explanation: The reference discusses the altered metabolic patterns of B cells, CD4(+) T cells, and myeloid cells (which include macrophages) and their contribution to lupus, which indirectly supports the involvement of these cell types in lupus mechanisms, but it does not specifically address immune complex formation directly.
  - reference: PMID:29925508
    supports: PARTIAL
    snippet: TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus.
    explanation: This reference demonstrates the role of specific plasma cells in the development of lupus nephritis, implying their role in immune complex-related pathology, but does not detail the direct involvement of B cells or macrophages in immune complex formation.
  - reference: PMID:34402453
    supports: PARTIAL
    snippet: B-lymphocytes are crucial in the pathogenesis of systemic lupus erythematosus (SLE), including autoantibody production, antigen presentation, co-stimulation, and cytokine secretion.
    explanation: The reference highlights the crucial role of B cells in the pathogenesis of SLE through mechanisms such as autoantibody production, which is critical for immune complex formation. However, it does not explicitly discuss the role of plasma cells or macrophages in the context given.
  - reference: PMID:22999705
    supports: PARTIAL
    snippet: C1q opsonized apoptotic cells also exert an immunosuppressive effect through cytokine regulation and the stimulation of additional opsonins by macrophages.
    explanation: This suggests that macrophages have a role in immune complex-mediated processes through cytokine regulation and opsonin stimulation, contributing to the immune system‚Äôs activity in lupus but does not detail the involvement of B cells or plasma cells in immune complex formation.
- name: Glomerular Immune Complex Deposition
  description: &gt;
    Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies
    lodge in kidney glomeruli, activating complement and recruiting inflammatory
    cells.
  locations:
  - preferred_term: Kidney
    term:
      id: UBERON:0002113
      label: kidney
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Lupus Nephritis
    description: Immune complex deposition in glomeruli triggers local inflammation and tissue damage.
  evidence:
  - reference: PMID:33841392
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges. Deposition of immune complexes in kidneys glomeruli are associated with lupus nephritis, determining SLE diagnosis.
    explanation: The literature supports the deposition of immune complexes in kidney glomeruli but does not cover skeletal joints, skin, heart, or lung in this context.
  - reference: PMID:30009962
    supports: SUPPORT
    snippet: LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins.
    explanation: This confirms immune complex deposition in kidneys.
- name: Cutaneous Immune Complex Deposition
  description: &gt;
    Immune complexes deposit at the dermal-epidermal junction and in vessel
    walls of the skin, leading to cutaneous manifestations of lupus.
  locations:
  - preferred_term: Skin
    term:
      id: UBERON:0002097
      label: skin of body
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:35872103
    supports: SUPPORT
    snippet: The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS).
    explanation: This paper directly establishes that autoantibodies form immune complexes which cause inflammatory damage to multiple organs in SLE.
  - reference: PMID:16572034
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
    explanation: The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.
- name: Synovial Immune Complex Deposition
  description: &gt;
    Immune complexes accumulate in synovial fluid and tissue of joints,
    activating complement and triggering inflammatory arthritis.
  locations:
  - preferred_term: Skeletal Joint
    term:
      id: UBERON:0000982
      label: skeletal joint
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:16572034
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
    explanation: The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.
  - reference: PMID:2860699
    supports: NO_EVIDENCE
    snippet: Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis.
    explanation: This confirms immune complex deposition in the heart.
  - reference: PMID:28900675
    supports: WRONG_STATEMENT
    snippet: Recent studies demonstrated an increased incidence of osteoporosis and peripheral and vertebral fractures in patients with SLE
    explanation: This reference does not mention the deposition of immune complexes in skeletal joints.
  - reference: PMID:158982
    supports: NO_EVIDENCE
    snippet: Abundant evidence currently exists to suggest that immune complexes play an important role in inflammatory diseases of the lung. ... systemic lupus erythematosus have been shown to be associated with the presence of immune complexes both in lung and in the serum.
    explanation: This confirms immune complex deposition in the lung.
- name: Inflammation And Tissue Damage
  evidence:
  - reference: PMID:22192660
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage.
    explanation: The article describes inflammation and immune complex deposition as mechanisms leading to tissue damage in SLE.
  - reference: PMID:36555640
    supports: SUPPORT
    snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
    explanation: The literature explains that inflammation and tissue damage are core mechanisms in the pathology of SLE due to immune system disturbances.
  - reference: PMID:28623084
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. A complex interaction of genetics, environment, and hormones leads to immune dysregulation and breakdown of tolerance to self-antigens, resulting in autoantibody production, inflammation, and destruction of end-organs.
    explanation: This article outlines inflammation as part of the immune dysregulation in SLE, leading to tissue damage in multiple organs.
  - reference: PMID:33841392
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges.
    explanation: The study identifies widespread inflammation and tissue damage as defining characteristics of SLE.
  - reference: PMID:37712757
    supports: SUPPORT
    snippet: In the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment.
    explanation: The review supports that inflammation and tissue damage are significant mechanisms in SLE affecting organs such as the skin, kidneys, and nervous system.
- name: Chronic Inflammation
  evidence:
  - reference: PMID:16572034
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues...
    explanation: The abstract confirms that inflammation is a key aspect of systemic lupus erythematosus pathogenesis.
  - reference: PMID:26330673
    supports: SUPPORT
    snippet: Systemic lupus erythematosus, the prototype systemic autoimmune disease, is characterized by extensive self-reactivity, inflammation, and organ system damage.
    explanation: The abstract clearly mentions inflammation as a characteristic feature of SLE.
  - reference: PMID:32237942
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ.
    explanation: The literature describes SLE as a chronic autoimmune disease affecting various organs, implying sustained inflammation over time.
  - reference: PMID:24992143
    supports: SUPPORT
    snippet: Recent evidence suggests that the inflammasome machinery is dysregulated in SLE, plays an important role in promotion of organ damage, and may mediate cross-talk between environmental triggers and the development of lupus.
    explanation: The abstract discusses the role of inflammasome and inflammation in organ damage associated with SLE, supporting the chronic inflammation mechanism.
  - reference: PMID:36555640
    supports: SUPPORT
    snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
    explanation: The literature describes inflammation and tissue damage due to immune complexes, which supports chronic inflammation as a mechanism of SLE.
- name: Flare-Ups
  description: The symptoms of lupus can worsen suddenly in episodes known as flares, which can be triggered by factors like stress, sunlight, and infections.
  evidence:
  - reference: PMID:26951252
    supports: SUPPORT
    snippet: These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms.
    explanation: This reference mentions the potential triggers for lupus flares, which include UV light (sunlight) and infections.
  - reference: PMID:26494589
    supports: SUPPORT
    snippet: Some triggers for these exacerbations have been identified, including infections, vaccines, pregnancy, environmental factors such as weather, stress and drugs.
    explanation: This reference specifically states that stress and infections can trigger lupus flares.
  - reference: PMID:22385883
    supports: SUPPORT
    snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
    explanation: This reference confirms that sunlight exposure can trigger lupus flares.
  - reference: PMID:30488801
    supports: NO_EVIDENCE
    snippet: The cutaneous manifestations that were present included malar rash 37.69%, photosensitivity 35.10%, discoid lupus 17.63%, and hair loss 39.29%.
    explanation: This reference discusses photosensitivity (sunlight) as a significant factor, aligning with the statement&#39;s mention of sunlight as a trigger.
- name: Type I Interferon Pathway Activation
  description: Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: type I interferon signaling pathway
    term:
      id: GO:0060337
      label: type I interferon signaling pathway
  evidence:
  - reference: PMID:24834763
    supports: SUPPORT
    snippet: An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE.
    explanation: This review describes the type I interferon gene signature in SLE, supporting chronic activation of the type I interferon pathway.
- name: TLR7/TLR9-Mediated Nucleic Acid Sensing
  description: B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: toll-like receptor signaling pathway
    term:
      id: GO:0002224
      label: toll-like receptor signaling pathway
  - preferred_term: toll-like receptor 7 signaling pathway
    term:
      id: GO:0034154
      label: toll-like receptor 7 signaling pathway
  - preferred_term: toll-like receptor 9 signaling pathway
    term:
      id: GO:0034162
      label: toll-like receptor 9 signaling pathway
- name: NETosis and Neutrophil Extracellular Trap Formation
  description: Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  - preferred_term: neutrophil extracellular trap formation
    term:
      id: GO:0036230
      label: neutrophil extracellular trap formation
- name: Age-Associated B Cell Expansion
  description: Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: B cell activation
    term:
      id: GO:0042113
      label: B cell activation
  - preferred_term: B cell differentiation
    term:
      id: GO:0030183
      label: B cell differentiation
- name: T Follicular Helper Cell Dysregulation
  description: T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.
  cell_types:
  - preferred_term: T follicular helper cell
    term:
      id: CL:0002038
      label: T follicular helper cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: T cell activation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: germinal center formation
    term:
      id: GO:0002467
      label: germinal center formation
- name: Impaired Apoptotic Cell Clearance
  description: Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.
  biological_processes:
  - preferred_term: apoptotic cell clearance
    term:
      id: GO:0043277
      label: apoptotic cell clearance
  - preferred_term: efferocytosis
    term:
      id: GO:0043277
      label: apoptotic cell clearance
- name: Complement Pathway Dysregulation
  description: Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.
  biological_processes:
  - preferred_term: complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  locations:
  - preferred_term: Kidney
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: Glomerulus
    term:
      id: UBERON:0000074
      label: renal glomerulus
- name: Epigenetic Dysregulation and T Cell Metabolic Reprogramming
  description: &gt;
    Aberrant DNA methylation, histone modifications, and metabolic reprogramming
    in T cells contribute to lupus pathogenesis. Hypomethylation of immune gene
    loci activates autoreactive T cells, while metabolic shifts including altered
    mTOR signaling and glutaminolysis support inflammatory T cell programs.
  cell_types:
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: Epigenetic Regulation of Gene Expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  - preferred_term: T Cell Differentiation
    term:
      id: GO:0030217
      label: T cell differentiation
  downstream:
  - target: Autoantibody Production
    description: Dysregulated T cell programs promote autoreactive B cell help and autoantibody production
  notes: &gt;
    Cluster 100 (ATF4, GLS, CBLB) from Zhu/Dann Perturb-seq shows OR=3.7 for SLE, the
    strongest signal for this metabolic/stress response regulatory program. DNA methylation
    changes are well-established in lupus T cells.
phenotypes:
- category: Cutaneoous
  name: Malar Rash
  frequency: FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:23846232
    supports: PARTIAL
    snippet: The most common clinical manifestations were malar rash (61.3%)...
    explanation: The literature supports that malar rash is a common manifestation of systemic lupus erythematosus (SLE), but it does not specifically categorize it under &#39;Cutaneous&#39;.
  - reference: PMID:16966017
    supports: PARTIAL
    snippet: &#39;There are 3 forms of cutaneous lupus: chronic cutaneous (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus.&#39;
    explanation: This reference discusses cutaneous forms of lupus but does not specifically mention malar rash as one of these types.
  - reference: PMID:17711886
    supports: PARTIAL
    snippet: The common symptoms of SLE in children and adolescents include... rash...
    explanation: This reference indicates that rash, which can include malar rash, is common in SLE, but it does not specifically categorize malar rash as &#39;Cutaneous&#39;.
  phenotype_term:
    preferred_term: Malar Rash
    term:
      id: HP:0025300
      label: Malar rash
- category: Cutaneoous
  name: Photosensitivity
  frequency: FREQUENT
  evidence:
  - reference: PMID:15379880
    supports: SUPPORT
    snippet: Photosensitivity is one the most common manifestations of lupus erythematosus.
    explanation: The literature directly mentions that photosensitivity is a common manifestation in lupus erythematosus, supporting the statement that it is a frequent phenotype.
  - reference: PMID:31909888
    supports: PARTIAL
    snippet: Fatigue, widespread pain, sleep dysfunction, and mood disorders are common symptoms in SLE.
    explanation: While this reference mentions common symptoms of SLE, it does not specifically address photosensitivity.
  - reference: PMID:30988213
    supports: PARTIAL
    snippet: The cutaneous manifestations of lupus erythematosus (LE) include LE-specific and LE-nonspecific skin lesions.
    explanation: The reference discusses cutaneous manifestations of LE but does not specifically highlight photosensitivity.
  - reference: PMID:31575058
    supports: PARTIAL
    snippet: The development of SLE is attributed to the breach of immunological tolerance and the interaction between SLE-susceptibility genes and various environmental factors.
    explanation: While the reference discusses factors contributing to the development of SLE, it does not explicitly address photosensitivity.
  - reference: PMID:23846232
    supports: PARTIAL
    snippet: The most common clinical manifestations were malar rash (61.3%), arthritis (52.3%), haematological disease (51.6%), oral ulcers (51%) and renal disease (40.6%).
    explanation: Photosensitivity is not specifically mentioned among the most common clinical manifestations in this study.
  - reference: PMID:29087262
    supports: PARTIAL
    snippet: Analysis revealed that photosensitivity, nephritis and thrombocytopenia were negatively associated with familial SLE.
    explanation: This reference suggests that photosensitivity is common in non-familial SLE, indirectly supporting the statement regarding its frequency.
  phenotype_term:
    preferred_term: Photosensitivity
    term:
      id: HP:0000992
      label: Cutaneous photosensitivity
- category: Musculoskeletal
  name: Arthritis
  frequency: FREQUENT
  evidence:
  - reference: PMID:19591780
    supports: SUPPORT
    snippet: Arthritis in systemic lupus erythematosus (SLE) is one of the most common disease manifestations. Nearly all joints can be affected by SLE, but hand and knee involvement are the most typical.
    explanation: This reference explicitly states that arthritis is one of the most common disease manifestations in patients with SLE.
  - reference: PMID:27742023
    supports: PARTIAL
    snippet: The precise nature of the disorder can be obscure and different disorders can present with similar symptoms, such as joint pain.
    explanation: The statement mentions joint pain, which is associated with arthritis and suggests that musculoskeletal symptoms are common in SLE.
  - reference: PMID:19013374
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune and inflammatory disease characterized by a variety of symptoms, including arthropathy. The clinical presentation of joint involvement varies, ranging from arthralgia without erosions or deformity to an erosive arthropathy and severe functional disability.
    explanation: This reference elaborates on the different forms of joint involvement in SLE, including arthropathy, which reinforces the statement that arthritis is a common musculoskeletal phenotype in SLE.
  - reference: PMID:32956154
    supports: PARTIAL
    snippet: Polyautoimmunity was recorded in 15 patients with RA (13.8%), 43 with SLE (41%), and 2 controls (2.2%). ... In SLE, joint damage (OR, 2.282; p = 0.038) and anti-RNP antibodies (OR, 5.095; p = 0.028) were risk factors for polyautoimmunity...
    explanation: This reference indicates a significant association between SLE and joint damage, further supporting the statement.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
- category: Renal
  name: Kidney Involvement
  evidence:
  - reference: PMID:36251502
    supports: SUPPORT
    snippet: Among 365 patients with SLE, 36% had LN.
    explanation: The study indicates that a significant portion of patients with Systemic Lupus Erythematosus (SLE) exhibit kidney involvement in the form of lupus nephritis (LN).
  - reference: PMID:330103
    supports: SUPPORT
    snippet: &#39;The pathologic abnormalities present in patients with SLE have been classified as follows: minimal lupus nephritis, mild (focal) proliferative lupus nephritis, severe (diffuse) proliferative lupus nephritis, and membranous lupus nephritis.&#39;
    explanation: The classification of pathologic abnormalities in SLE patients includes various forms of lupus nephritis, which confirms kidney involvement.
  - reference: PMID:30454753
    supports: SUPPORT
    snippet: Patients with early onset SLE tend to have a greater genetic component to their disease cause, more multisystemic involvement, and a more severe disease course, which includes greater risks for developing nephritis and end-stage kidney disease.
    explanation: This study highlights that childhood-onset SLE has a high risk of developing nephritis, underlining kidney involvement as a significant phenotype.
- category: Hematologic
  name: Kidney Involvement
  evidence:
  - reference: PMID:32725543
    supports: NO_EVIDENCE
    snippet: Kidney involvement occurs in over 50% of children and treatment decisions are guided by the histological classification.
    explanation: The study discusses kidney involvement in pediatric SLE but does not categorize it as &#34;Hematologic phenotype&#34;.
  - reference: PMID:22312827
    supports: NO_EVIDENCE
    snippet: Systemic lupus erythematosus (SLE) is a chronic syndrome with unknown etiology and polymorphic clinical picture... Severe SLE involves glomerulonephritis, complications in the central nervous system, cardiac and pulmonary complications and major changes in the blood.
    explanation: The literature describes both hematologic changes and kidney involvement separately but does not categorically combine them into a single phenotype.
  - reference: PMID:14717922
    supports: NO_EVIDENCE
    snippet: The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis... The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions.
    explanation: This paper details the classification of lupus nephritis but does not mention it as a hematologic phenotype.
  - reference: PMID:36251502
    supports: NO_EVIDENCE
    snippet: &#39;CONCLUSION: This study aids in the recognition of the demographic, clinical, laboratory features, and the histological patterns of LN patients in Saudi Arabia, that probably has a role in the development and disease progression.&#39;
    explanation: This study focuses on the prevalence and patterns of lupus nephritis but does not treat it as a hematologic phenotype.
- category: Renal
  frequency: FREQUENT
  name: Lupus Nephritis
  notes: Inflammation of the kidneys, can lead to renal failure
  evidence:
  - reference: PMID:16530602
    supports: SUPPORT
    snippet: Lupus nephritis is one of the more serious manifestations of the systemic autoimmune disease, systemic lupus erythematosus, and is associated with considerable morbidity and even mortality.
    explanation: The reference confirms that lupus nephritis is a serious and frequent manifestation of systemic lupus erythematosus (SLE).
  - reference: PMID:32295853
    supports: SUPPORT
    snippet: The frequency of endstage renal disease (ESRD) from systemic lupus erythematosus (SLE) in the United States has not improved over the last few decades in large population datasets.
    explanation: The reference indicates the prevalence of renal complications, including end-stage renal disease, in SLE patients.
  - reference: PMID:35775489
    supports: SUPPORT
    snippet: Lupus nephritis (LN) is common in people with systemic lupus erythematosus (SLE) and advances, almost invariably, to end-stage renal disease (ESRD).
    explanation: The reference supports that lupus nephritis is a common and serious renal manifestation in SLE, often leading to ESRD.
  - reference: PMID:22192934
    supports: SUPPORT
    snippet: Renal involvement is frequent (20 to 50% of cases) during the course of systemic lupus erythematosus (SLE).
    explanation: The reference states that renal involvement, including lupus nephritis, is frequent in SLE patients.
  phenotype_term:
    preferred_term: Lupus Nephritis
    term:
      id: HP:0033726
      label: Lupus nephritis
- category: Hematologic
  frequency: FREQUENT
  name: Leukopenia
  notes: Low white blood cell count
  evidence:
  - reference: PMID:26170228
    supports: SUPPORT
    snippet: The prevalence of leukopenia is reported in 22-41.8% of cases.
    explanation: The study reports that leukopenia is prevalent in 22-41.8% of SLE cases, indicating that leukopenia is a frequent hematologic abnormality in SLE patients.
  - reference: PMID:27590999
    supports: PARTIAL
    snippet: TCP was the most prevalent hematological abnormality evident in 15%, more than leucopenia (14%) and anemia (2%).
    explanation: Although thrombocytopenia was the most prevalent, leukopenia was still present in 14% of the cases, supporting the statement that leukopenia is a frequent hematologic abnormality in SLE patients.
  - reference: PMID:8130682
    supports: PARTIAL
    snippet: The increased risk of infection in patients with SLE is due in part to changes in the white blood cells though treatments do not yet aim to modify these.
    explanation: The study mentions changes in white blood cells, including leukopenia, as a common hematologic manifestation in SLE patients.
  - reference: PMID:15580984
    supports: SUPPORT
    snippet: &#39;In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis); 2) leukopenia (&lt;4000/microL on two or more occasions)... is now considered as a single hematologic disorder.&#39;
    explanation: The ACR criteria include leukopenia as a significant hematologic disorder in the diagnosis of SLE, supporting its frequent occurrence.
  phenotype_term:
    preferred_term: Leukopenia
    term:
      id: HP:0001882
      label: Decreased total leukocyte count
- category: Hematologic
  frequency: FREQUENT
  name: Thrombocytopenia
  notes: Low platelet count
  evidence:
  - reference: PMID:32896257
    supports: PARTIAL
    snippet: Thrombocytopenia was classified as mild (100-149x109/L), moderate (31-99x109/L) or severe (&lt;/=30x109/L platelets).
    explanation: The study shows that thrombocytopenia is a common occurrence in SLE patients, with a significant portion experiencing various degrees of thrombocytopenia.
  - reference: PMID:12481500
    supports: SUPPORT
    snippet: Thrombocytopenia is common, autoimmune and associated with a decreased survival.
    explanation: This reference confirms that thrombocytopenia is a common hematologic abnormality in SLE patients.
  - reference: PMID:15580984
    supports: SUPPORT
    snippet: Thrombocytopenia (&lt; 100,000/microL in the absence of offending drugs) is now considered as a single hematologic disorder.
    explanation: This review highlights thrombocytopenia as a significant hematologic criterion for diagnosing SLE.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Hematologic
  frequency: OCCASIONAL
  name: Hemolytic Anemia
  notes: Destruction of red blood cells
  evidence:
  - reference: PMID:12481500
    supports: NO_EVIDENCE
    snippet: &#39;Anaemia is the most common hematological abnormality in SLE, it is multifactorial. The most common form of anaemia is that of chronic disease, and it is relate with inflammatory cytokines. Other tips of anaemia are: iron deficiency anaemia, autoimmune haemolytic anaemia, pure red cell aplasia.&#39;
    explanation: The abstract mentions that autoimmune hemolytic anemia is one of the types of anemia in SLE but does not provide information about its frequency.
  - reference: PMID:36469203
    supports: PARTIAL
    snippet: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that would potentiate many pathological complications, including hemolytic anemia.
    explanation: This reference confirms that hemolytic anemia is one of the complications of SLE.
  - reference: PMID:15580984
    supports: PARTIAL
    snippet: &#39;In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis)... is now considered as a single hematologic disorder.&#39;
    explanation: The ACR criteria for diagnosing SLE includes hemolytic anemia as one of the hematologic disorders.
  - reference: PMID:30631001
    supports: PARTIAL
    snippet: One month prior, she had been diagnosed with Evans syndrome (haemolytic anemia with positive Coombs test and thrombocytopenia)... Further examination revealed positive for ANA, anti-SSA, and diagnosis of SLE was established.
    explanation: This case study describes a patient with hemolytic anemia who was diagnosed with SLE.
  phenotype_term:
    preferred_term: Hemolytic Anemia
    term:
      id: HP:0001878
      label: Hemolytic anemia
- category: Cardiac
  frequency: OCCASIONAL
  name: Pericarditis
  notes: Inflammation of the pericardium (lining around the heart)
  evidence:
  - reference: PMID:16218467
    supports: REFUTE
    snippet: Pericarditis is the most common cardiac abnormality in systemic lupus erythematosus (SLE) patients...
    explanation: The literature states that pericarditis is the most common cardiac abnormality in SLE patients, not occasional.
  - reference: PMID:31507126
    supports: REFUTE
    snippet: Several diseases are frequently associated with such manifestations. They include systemic lupus erythematosus...
    explanation: The literature indicates that systemic lupus erythematosus is frequently associated with pericarditis, not occasionally.
  - reference: PMID:33216192
    supports: REFUTE
    snippet: Pericarditis can be present in the context of systemic inflammatory rheumatic diseases...
    explanation: The literature suggests that pericarditis can commonly be present in systemic inflammatory rheumatic diseases, including SLE.
  phenotype_term:
    preferred_term: Pericarditis
    term:
      id: HP:0001701
      label: Pericarditis
- category: Pulmonary
  frequency: OCCASIONAL
  name: Pleuritis
  notes: Inflammation of the pleura (lining around the lungs)
  evidence:
  - reference: PMID:8153398
    supports: PARTIAL
    snippet: The pleuropulmonary manifestation of systemic lupus erythematous (SLE) are pleuritis, acute lupus pneumonitis, chronic interstitial lung disease with fibrosis, alveolar hemorrhage, respiratory muscle and diaphragmatic dysfunction, atelectasis, bronchiolitis obliterans, pulmonary vascular disease with pulmonary hypertension, and pulmonary embolism.
    explanation: The article explicitly lists pleuritis as one of the pleuropulmonary manifestations of SLE.
  - reference: PMID:25318967
    supports: PARTIAL
    snippet: We investigated the clinical characteristics of pleural effusion in systemic lupus erythematosus (SLE). A prospective analysis of 17 SLE patients with pleural effusion (seven lupus pleuritis, eight transudative effusions and two parapneumonic effusions) was performed.
    explanation: The prospective analysis found lupus pleuritis in SLE patients, supporting the statement.
  - reference: PMID:12055395
    supports: PARTIAL
    snippet: Fortunately, pleuritis in systemic lupus erythematosus is not usually as life threatening as may be the renal or central nervous system complications. Nevertheless, pleuritis does occur in systemic lupus erythematosus and may be a significant cause of morbidity.
    explanation: The article confirms that pleuritis occurs in SLE patients.
  phenotype_term:
    preferred_term: Pleuritis
    term:
      id: HP:0002102
      label: Pleuritis
- category: Neuropsychiatric
  frequency: OCCASIONAL
  name: Seizures
  evidence:
  - reference: PMID:33626435
    supports: PARTIAL
    snippet: The prevalence of explicit episodes of seizures among SLE patients, varies from 2 to 8%.
    explanation: The prevalence range of 2 to 8% suggests that seizures are not very common but occur at a noticeable rate, which could be interpreted as occasional.
  - reference: PMID:12136236
    supports: PARTIAL
    snippet: Seizures and psychosis are neuropsychiatric (NP) manifestations of a large number of systemic lupus erythematosus (SLE) patients.
    explanation: This reference supports the idea that seizures are a recognized neuropsychiatric manifestation of SLE, implying they occur with some regularity.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
- category: Neuropsychiatric
  frequency: OCCASIONAL
  name: Psychosis
  evidence:
  - reference: PMID:30375754
    supports: PARTIAL
    snippet: Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status.
    explanation: The study indicates that psychosis is an infrequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), which suggests it is not common but does occur occasionally. This partially supports the statement that psychosis is an &#39;occasional&#39; manifestation.
  - reference: PMID:37771217
    supports: PARTIAL
    snippet: Psychosis is a rare NPSLE manifestation that can occur at any phase of the illness; 21% of SLE-related psychosis cases occur at the onset of SLE.
    explanation: This case report describes psychosis as a rare manifestation of NPSLE, occurring in 21% of cases at the onset of SLE. While &#39;rare&#39; and &#39;occasional&#39; are not identical, they both imply infrequency, partially supporting the statement.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
biochemical:
- name: Anti-Nuclear Antibodies (ANA)
  specificity: High
  frequency: 98%
  presence: Positive
  evidence:
  - reference: PMID:32884126
    supports: PARTIAL
    snippet: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction.
    explanation: While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature.
  - reference: PMID:34996081
    supports: PARTIAL
    snippet: The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent.
    explanation: The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate.
  - reference: PMID:23456415
    supports: PARTIAL
    snippet: Antinuclear antibody was present in 79.6%.
    explanation: This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE.
  - reference: PMID:22301032
    supports: PARTIAL
    snippet: Based on some research evidence and consensus, the diagnosis of pSLE is unlikely if the ANA is negative, and most patients with SLE have a positive ANA at a titer ‚â•1:160
    explanation: While the statement indicates the common presence of ANA in SLE, it does not confirm the 98% figure.
- name: Anti-dsDNA Antibodies
  specificity: High
  presence: Positive
  evidence:
  - reference: PMID:29224677
    supports: PARTIAL
    snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens.
    explanation: This supports the presence of anti-dsDNA antibodies in patients with SLE.
  - reference: PMID:20414746
    supports: PARTIAL
    snippet: Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN.
    explanation: This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis.
  - reference: PMID:35049409
    supports: SUPPORT
    snippet: Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE).
    explanation: This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE.
  - reference: PMID:2203596
    supports: SUPPORT
    snippet: The prevalence of anti-dsDNA antibodies was strongly influenced by the selection criteria of the patient.
    explanation: This indicates that anti-dsDNA antibodies are present in SLE patients, even though their prevalence can vary based on specific criteria.
- name: Anti-Smith Antibodies
  specificity: High
  presence: Positive
  evidence:
  - reference: PMID:29503043
    supports: SUPPORT
    snippet: One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE.
    explanation: The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity.
- name: Anti-Histone Antibodies
  notes: Common in drug-induced lupus.
  presence: Positive
  evidence:
  - reference: PMID:35383534
    supports: SUPPORT
    snippet: Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE).
    explanation: The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus.
  - reference: PMID:35383534
    supports: PARTIAL
    snippet: AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs.
    explanation: While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents.
genetic:
- name: HLA-DR2
  presence: Positive
  evidence:
  - reference: PMID:37801591
    supports: PARTIAL
    snippet: HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis)
    explanation: The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population.
- name: HLA-DR3
  presence: Positive
  evidence:
  - reference: PMID:17910142
    supports: PARTIAL
    snippet: A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01).
    explanation: The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE.
  - reference: PMID:6103441
    supports: NO_EVIDENCE
    snippet: It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE.
    explanation: This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE.
- name: PTPN22
  association: Associated
  evidence:
  - reference: PMID:31232672
    supports: SUPPORT
    snippet: We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p &lt; 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE.
    explanation: The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE.
- name: STAT4
  association: Associated
  evidence:
  - reference: PMID:23912645
    supports: SUPPORT
    snippet: Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE.
    explanation: The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE.
  - reference: PMID:31082500
    supports: SUPPORT
    snippet: Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4...
    explanation: This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data.
  - reference: PMID:34525002
    supports: NO_EVIDENCE
    snippet: &#39;The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in Salvador, Bahia, Brazil.&#39;
    explanation: The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE.
- name: IRF5
  association: Associated
  notes: Interferon regulatory factor 5; transcription factor driving type I interferon pathway activation
  evidence:
  - reference: PMID:20962850
    supports: SUPPORT
    snippet: Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE...
    explanation: The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE.
  - reference: PMID:26233721
    supports: SUPPORT
    snippet: This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE...
    explanation: The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations.
  - reference: PMID:23251221
    supports: SUPPORT
    snippet: Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis.
    explanation: The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease.
  - reference: PMID:20453440
    supports: SUPPORT
    snippet: Recent large-scale studies in the Caucasian populations identified many new susceptibility genes to systemic lupus erythematosus (SLE)... In IRF5, the risk haplotype in Caucasians was not present in Japanese... All of these genes were associated with SLE...
    explanation: The study confirms that IRF5 is associated with SLE in both Caucasian and Japanese populations.
  - reference: PMID:36245280
    supports: SUPPORT
    snippet: IRF5 plays a crucial role in the development of lupus... Genome-wide association studies have identified several systemic lupus erythematosus (SLE) risk single-nucleotide polymorphisms (SNPs) enriched in the IRF5 locus.
    explanation: The study identifies IRF5 as playing a key role in SLE development with confirmed risk SNPs.
- name: TLR7
  association: Associated
  notes: Toll-like receptor 7; B cell-intrinsic driver promoting RNA-associated autoantibodies and disease activity
- name: TLR9
  association: Associated
  notes: Toll-like receptor 9; can exert counter-regulatory effects, restraining age-associated B cell differentiation
- name: MYD88
  association: Associated
  notes: Myeloid differentiation primary response 88; adaptor protein downstream of TLR7/9 required for autoantibody production
- name: CYBB
  association: Associated
  notes: Cytochrome b-245 beta chain (NOX2); NOX2-generated ROS negatively regulate TLR7 signaling; loss exacerbates disease
- name: TNFSF13B
  association: Associated
  notes: TNF superfamily member 13b (BAFF); supports B cell survival and extrafollicular responses integrated with IFN/Tfh circuits
- name: IL21
  association: Associated
  notes: Interleukin 21; Tfh-derived cytokine driving B cell differentiation to plasma cells
- name: BACH2
  association: GWAS
  notes: Transcription factor regulating Treg/effector T cell balance and B cell class switching
- name: TNFAIP3
  association: GWAS
  notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: STAT3
  association: GWAS
  notes: Signal transducer mediating Th17 differentiation via JAK-STAT pathway
- name: IL10
  association: GWAS
  notes: Anti-inflammatory cytokine critical for immune tolerance
- name: EGR2
  association: GWAS
  notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: ETS1
  association: GWAS
  notes: Transcription factor regulating T and B cell development and immune cell differentiation
- name: IRF4
  association: GWAS
  notes: Transcription factor essential for Th17 and Th2 cell differentiation and plasma cell development
- name: IRF8
  association: GWAS
  notes: Interferon regulatory factor controlling myeloid cell development and type I interferon response
- name: IKZF1
  association: GWAS
  notes: Ikaros transcription factor essential for lymphocyte development and differentiation
- name: SMAD3
  association: GWAS
  notes: TGF-beta signaling mediator regulating T cell differentiation and immune tolerance
- name: REL
  association: GWAS
  notes: NF-kB subunit c-Rel controlling lymphocyte activation and survival
- name: PRDM1
  association: GWAS
  notes: Blimp-1 transcription factor regulating T cell and B cell terminal differentiation
environmental:
- name: UV Exposure
  notes: Exacerbates disease activity.
  presence: Positive
  evidence:
  - reference: PMID:24763542
    supports: SUPPORT
    snippet: While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE.
    explanation: The literature clearly states that UV radiation exposure may exacerbate pre-existing lupus, which supports the statement.
  - reference: PMID:22385883
    supports: SUPPORT
    snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
    explanation: The study investigates the seasonal variation in lupus flares and correlates increased flares with increased temperature and sunshine, supporting the statement that UV exposure exacerbates disease activity.
  exposure_term:
    preferred_term: UV light exposure
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
- name: Infection
  notes: Can trigger or worsen disease symptoms.
  presence: Positive
  evidence:
  - reference: PMID:36332998
    supports: PARTIAL
    snippet: This review focuses on SLE risk potentially associated with environmental factors including infections.
    explanation: The paper identifies infections as one of the environmental factors potentially associated with the risk of SLE, thereby supporting the statement that infections can trigger or worsen disease symptoms in SLE.
  - reference: PMID:25022358
    supports: SUPPORT
    snippet: New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described.
    explanation: This review mentions infections, specifically Epstein-Barr virus, as triggers for autoimmunity, which supports the notion that infections can influence SLE disease activity.
  - reference: PMID:38146370
    supports: PARTIAL
    snippet: The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated.
    explanation: This study supports the connection between infections (specifically EBV) and SLE, further establishing that infections can trigger or worsen SLE symptoms.
  exposure_term:
    preferred_term: Infectious agent exposure
    term:
      id: ECTO:3000000
      label: exposure to organism
- name: Stress
  notes: Psychological stress can trigger flares.
  presence: Positive
  evidence:
  - reference: PMID:25216337
    supports: PARTIAL
    snippet: It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals
    explanation: This reference discusses various environmental factors that can trigger SLE flares, which supports the notion that stress, as an environmental factor, can do so as well.
  - reference: PMID:36537191
    supports: SUPPORT
    snippet: In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined.
    explanation: This reference directly supports the statement that psychological stress can trigger and worsen SLE flares.
  - reference: PMID:36535611
    supports: PARTIAL
    snippet: Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE.
    explanation: This reference indicates a link between stress-related disorders and the development or worsening of SLE.
  exposure_term:
    preferred_term: Psychological stress exposure
animal_models:
- species: Mouse
  genes:
  - preferred_term: FAS
    term:
      id: hgnc:11920
      label: FAS
  genotype: MRL/lpr strain
  alleles:
  - FAS lpr
  description: genetically prone to develop lupus-like symptoms and APS
  evidence:
  - reference: PMID:25183233
    supports: SUPPORT
    snippet: Mouse models of autoimmunity, such as (NZB√óNZW)F1, MRL/MpJ-Fas(lpr) (MRL-lpr) and BXSB mice, spontaneously develop systemic lupus erythematosus (SLE)-like syndromes with heterogeneity and complexity that characterize human SLE
    explanation: This excerpt supports the statement by confirming that MRL/MpJ-Fas(lpr) (MRL-lpr) mice develop SLE-like syndromes.
  - reference: PMID:14550881
    supports: NO_EVIDENCE
    snippet: The association of HLA-DR4, -DR7, -DRw53 and -DQB1*0302 with aCL... can also be found in SLE...
    explanation: This excerpt supports the statement, indicating that there is an association between HLA alleles and SLE in MRL-lpr mice.
  - reference: PMID:38113962
    supports: SUPPORT
    snippet: Sle1 and Faslpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus
    explanation: The snippet confirms that Fas(lpr) is a lupus susceptibility locus leading to SLE manifestations.
  - reference: PMID:28078597
    supports: SUPPORT
    snippet: This is characterized by the development of arthritis and immune complex glomerulonephrosis making this strain a useful model for studying systemic lupus erythematosus.
    explanation: This excerpt supports the statement by describing the MRL-lpr strain as a useful model for studying SLE, noting the development of relevant symptoms.
  - reference: PMID:18325838
    supports: PARTIAL
    snippet: breeding the ApoE(-/-) defect onto MRL/lpr mice all caused a modest increase of atherosclerosis...
    explanation: This excerpt partially supports the statement, indicating that breeding the ApoE(-/-) defect into MRL/lpr mice results in an increase in atherosclerosis (related to APS). However, it does not explicitly conclude a genetic predisposition to APS.
- species: Mouse
  background: (NZB/BlNJ x NZW/LacJ)F1/J
  evidence:
  - reference: PMID:36211391
    supports: PARTIAL
    snippet: The (NZW√óBXSB) F1 lupus-prone male mouse model of this disease is potentially useful to study mechanism and treatment modalities, but there is a lack of information about this model&#39;s characterization and disease progression
    explanation: The reference discusses the (NZWxBXSB) F1 model rather than the (NZB/BlNJ x NZW/LacJ) F1/J model.
  - reference: PMID:31943822
    supports: SUPPORT
    snippet: &#39;METHODS: Lupus-prone (NZB √ó NZW)F1 mice that had been DNA-vaccinated with plasmids encoding Hsp70 and controls were monitored for lupus disease parameters including anti-double stranded DNA (anti-dsDNA) autoantibodies and cytokines using enzyme-linked immunosorbent assay, and for kidney function and pathology&#39;
    explanation: This reference supports the use of (NZB x NZW)F1 mice as a model for SLE.
treatments:
- name: Type I Interferon Receptor Antagonist
  description: Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: Anifrolumab approved for moderate-to-severe SLE; biomarker-guided therapy
  evidence:
  - reference: PMID:28130918
    supports: SUPPORT
    snippet: Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE
    explanation: This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures.
- name: B Cell Depletion Therapy
  description: Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: CAR-T cell therapy has induced drug-free remissions in early clinical experiences
- name: BAFF Pathway Inhibition
  description: Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: Integrates BAFF/IFN biomarkers with therapeutic selection
  evidence:
  - reference: PMID:22127708
    supports: SUPPORT
    snippet: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE
    explanation: This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo.
- name: Immunosuppressive Therapy
  description: Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: Standard immunosuppressive agents for disease control
- name: Supportive Care
  description: Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  notes: Organ-specific symptomatic management
review_notes: &#34;SLE is a complex autoimmune disorder that can affect multiple organ systems.\nThe hallmark is production of autoantibodies. Diagnosis requires a combination \nof clinical findings and positive antibody tests (ANA, anti-dsDNA, anti-Sm).\nFrequency of involvement of each organ system is variable. Renal and CNS involvement\nare major sources of morbidity. Disease course is characterized by periods of \nflare and remission.&#34;
disease_term:
  preferred_term: systemic lupus erythematosus
  term:
    id: MONDO:0007915
    label: systemic lupus erythematosus
classifications:
  harrisons_chapter:
  - classification_value: musculoskeletal system disorder
  - classification_value: connective tissue disease
  - classification_value: autoimmune disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Systemic_Lupus_Erythematosus.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>